Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ONAWA: Onapristone as Preoperative Treatment for Postmenopausal Women With HR+/HER2- Breast Cancer
NCT04142892Phase 1Completed
- Sponsor
- SOLTI
- Start
- Nov 2020
- Primary completion
- Apr 2021
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of onapristone extended release in breast cancer, sponsored by SOLTI. Primary endpoint: Complete Cell Cycle Arrest at 3 weeks. Started Nov 2020; status: completed.
02
Drugs
onapristone extended release
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04142892.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04142892.